MI-LINEAGE-LOGISTICS-LLC
11.1.2022 08:03:03 CET | Business Wire | Press release
Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today announced the acquisitions of Van Tuyl Logistics, H&S Coldstores and Frigocare Rotterdam BV. These strategic transactions will strengthen Lineage’s portfolio of end-to-end logistics solutions in the region and grow Lineage’s presence in the Netherlands by more than 250,000 cubic metres of capacity.
Based in Gameren, Van Tuyl Logistics is a Dutch provider of temperature-controlled logistics that specialises in refrigerated and frozen transport. Van Tuyl employs a modern fleet of 60 trucks and 90 trailers with a self-owned repair station, in addition to warehousing services for 30,000 pallet spaces at different temperatures and a real estate holding division.
“We are pleased to welcome Van Tuyl Logistics into the One Lineage Family as we continue to build momentum and further expand our European operations,” said Harld Peters, Senior Vice President, Europe at Lineage. “The Netherlands remains a critical hub for the food cold chain within the European market, given its central location and accessibility to key seaports and inland terminals. Accordingly, the addition of Van Tuyl will help Lineage to connect more points across our customers’ extended supply chains.”
“We know that Lineage is the right partner for the next stage in our company’s history and in our ambition to reimagine the journey of food,” said Richard van Tuijl, General Director of Van Tuyl Logistics. “Our end-to-end solutions complement Lineage’s strong and growing presence in Europe, and we are confident that our customers will continue to be well-served as we combine our logistics and cold storage operations.”
Lineage also acquired Dutch provider H&S Coldstores and its logistics forwarding business from the H&S Group, Europe’s largest intermodal Liquid Food operator.
Headquartered in Beneden-Leeuwen, H&S Coldstores provides end-to-end juice supply chain services, including transport, warehousing, customs, production, processing, laboratory testing, and packaging solutions. The logistics forwarding business from H&S Group also offers a pan-European network of more than 250 privately owned and subcontracted vehicles as well as more than 1,500 tank units for the liquid foodstuff industry.
In total, this acquisition will add a capacity of 48,000 tonnes to Lineage’s footprint in Europe. The H&S Coldstores facilities in Elst and Tiel will be moved to a new location in a newly built facility, closer to other existing facilities in Beneden-Leeuwen. This new cold store near the port of Rotterdam will be operational by mid-2022. This new facility complies with the highest LEED/BREEAM status and will make use of solar energy.
“H&S Coldstores is another fantastic example of our continued investment in the Netherlands,” said Peters of Lineage. “In particular, their differentiated juice-blending services greatly complement our existing capabilities via our recent acquisition of Kloosterboer, and will further diversify our business offering across the cold chain.”
Finally, Lineage also announced today the acquisition of the Dutch facilities of Frigocare Rotterdam BV, a company specialized in handling imports of frozen fish mainly from the North Atlantic and Asia to the Port of Rotterdam. The facility is located near an existing Lineage facility in the same harbour and will add 15,000 pallet positions in its 20,000 square metre warehouses to Lineage’s operations in Rotterdam.
Financial terms of the transactions were not disclosed.
About Lineage Logistics
Lineage Logistics is one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 19 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network, and development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com )
About Van Tuyl Logistics
Van Tuyl Logistics is a Dutch cold chain logistics company, active in The Netherlands since its inception in 1983. The company specialises in refrigerated and frozen transport of fresh produce and other foodstuffs. Aside from its transport activities, Van Tuyl Logistics also provides storage solutions via their cold storage facility, located in Gameren, The Netherlands.
About H&S Group
H&S Group is Europe’s largest intermodal Liquid Food operator. The company is headquartered in Barneveld, The Netherlands and provides end-to-end supply chain services. H&S Group also offers a pan-European network of more than 250 privately owned and subcontracted vehicles, and more than 1,500 tank units for the liquid foodstuff industry. H&S Coldstores owns three facilities in Tiel, Beneden-Leeuwen and Elst, where it provides the following services: transport, warehousing, customs, production, processing, laboratory testing, and packaging solutions.
About Frigocare Rotterdam
Frigocare Rotterdam BV is a cold store company specialised in food logistics, specifically handling frozen fish from the North Atlantic and Asia to the port of Rotterdam, The Netherlands. The company provides the following services aside from storage: container reception, border inspection, sorting, palletizing, (re)packing and (un)loading of various delicate cargo, mostly seafood, under EU-license.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110006028/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
